Related references
Note: Only part of the references are listed.Efficacy of the MEK inhibitor cobimetinib for wild-type BRAF Erdheim-Chester disease
Fleur Cohen Aubart et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Histiocytoses: emerging neoplasia behind inflammation
Julien Haroche et al.
LANCET ONCOLOGY (2017)
Clinical and Radiologic Responses to Cladribine for the Treatment of Erdheim-Chester Disease
Gaurav Goyal et al.
JAMA ONCOLOGY (2017)
Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study)
Fleur Cohen Aubart et al.
BLOOD (2017)
Diverse and Targetable Kinase Alterations Drive Histiocytic Neoplasms
Eli L. Diamond et al.
CANCER DISCOVERY (2016)
Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages
J.-F. Emile et al.
BLOOD (2016)
Reproducible and Sustained Efficacy of Targeted Therapy With Vemurafenib in Patients With BRAFV600E-Mutated Erdheim-Chester Disease
Julien Haroche et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Complete remission of critical neurohistiocytosis by vemurafenib
Philipp Euskirchen et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease
Jean-Francois Emile et al.
BLOOD (2014)
Consensus guidelines for the diagnosis and clinical management of Erdheim-Chester disease
Eli L. Diamond et al.
BLOOD (2014)
Erdheim-Chester Disease
Julien Haroche et al.
CURRENT RHEUMATOLOGY REPORTS (2014)
The multifaceted clinical presentations and manifestations of Erdheim-Chester disease: comprehensive review of the literature and of 10 new cases
Giulio Cavalli et al.
ANNALS OF THE RHEUMATIC DISEASES (2013)
High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses
Julien Haroche et al.
BLOOD (2012)
CNS involvement and treatment with interferon-α are independent prognostic factors in Erdheim-Chester disease: a multicenter survival analysis of 53 patients
Laurent Arnaud et al.
BLOOD (2011)